Compare UVE & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | ODTX |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2025 |
| Metric | UVE | ODTX |
|---|---|---|
| Price | $42.32 | $26.39 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 187.1K | 126.3K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 3.93 | N/A |
| Revenue | ★ $1,603,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | ★ 5.48 | N/A |
| 52 Week Low | $24.03 | $15.10 |
| 52 Week High | $45.15 | $24.77 |
| Indicator | UVE | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 74.10 |
| Support Level | $41.88 | $19.84 |
| Resistance Level | $43.68 | N/A |
| Average True Range (ATR) | 1.04 | 1.85 |
| MACD | -0.26 | 0.50 |
| Stochastic Oscillator | 25.18 | 99.88 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.